Magazine Article | December 7, 2017

Virtual And Variable: Two Visions For Biopharma Outsourcing In 2018

Source: Life Science Leader

By Louis Garguilo, Chief Editor, Outsourced Pharma
Follow Me On Twitter @Louis_Garguilo

Regarding the trends identified by the biopharma executives interviewed for this discussion on the state and future of outsourcing, I’m reminded of the tongue-in-cheek reply as to why people — and organizations — make some of the decisions they do: “Because we can.” Perhaps a better way to say that is, because they have become enabled. In our case, we are witnessing decisions to create new biotech models for drug development and new approaches to externalization at pharmaceutical companies, because outsourcing has become a multifaceted and trustworthy enabler. Outsourcing today de-risks creation through externalization. Biopharma executives are now empowered to formulate these new business and operating models to pursue both financial and scientific objectives.